Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Upcoming 2013 Investor Conference Presentation

Key Takeaway: Regeneron Announces Upcoming 2013 Investor Conference Presentation

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,Dec. 4, 2013/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its presentation at the Oppenheimer 24thAnnual Healthcare Conference onWednesday, December 11, 2013.  The presentation is scheduled for10:05 a.m. Eastern Timeand may be accessed through the Company's web site,www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.
About Regeneron PharmaceuticalsRegeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visitwww.regeneron.com.
Contact Information:
Manisha Narasimhan, Ph.D. Peter Dworkin
Investor Relations Corporate Communications
914.847.5126 914.847.7640
[email protected] [email protected]
Last updated: Dec 4, 2013